The Company also announced two additions to the senior administration team.

Acetylon Pharmaceuticals to utilise additional financing in multiple myeloma medication development Acetylon Pharmaceuticals, Inc. Announced today that it has shut on a $2 million expense from a fresh undisclosed private investor to bring its total financing to $9.25 million. This fresh investment shall convert to stock within the next substantial round of preferred equity funding. The Company also announced two additions to the senior administration team. Simon S. Jones, Ph.D., was appointed Vice President, Biology and Preclinical Advancement and John H. Van Duzer, Ph.D., was appointed Vice President, Manufacturing and Chemistry. Acetylon is usually applying its scientific expertise to the advancement of small molecule HDAC inhibitors that build upon the confirmed therapeutic potential of HDAC inhibition with enhanced target selectivity.Palmer, M.D., Ph.D., David Cunningham, M.D., Alan Anthoney, M.D., Anthony Maraveyas, M.D., Ph.D., Srinivasan Madhusudan, M.D., Ph.D., Tim Iveson, M.D., Sharon Hughes, B.Sc., Stephen P. Pereira, M.D., Ph.D., Michael Roughton, M.Sc., and John Bridgewater, M.D., Ph.D. For the ABC-02 Trial Investigators: Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Biliary tract cancer is an uncommon cancer in formulated countries. There are approximately 1200 new cases in the United Kingdom1 and 9000 new cases in the United States per year, although the incidence is increasing, linked to gallstone disease perhaps.